Common infections role in 1918 influenza pandemic

31 August 2008

Two new studies of the 1918 Spanish influenza pandemic, which killed an estimated 50 million people, have concluded that common bacterial infections were responsible for most deaths among people who had been weakened by the virus. Anthony Fauci, director of the US National Institute of Allergy and Infectious Diseases, warned that "we have to realize that it isn't just antivirals that we need," in the event of a new pandemic, possibly triggered by a mutated strain of avian influenza (Marketletters passim).

The two studies were published by the Journal of Infectious Diseases on-line and the August edition of Emerging Infectious Diseases. The Los Angeles Times reports that a severe immune reaction to the flu virus probably affected most victims of the pandemic, however, most deaths occurred later. It now appears that the damaged lining of the lungs created an opportunity for other infections to trigger fatal pneumonia. Dr Fauci called for the urgent development of new antibiotics, especially against Staphylococcus aureus.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight